Phibro Animal Health (PAHC) has confirmed a quarterly cash dividend of $0.12 per share on both its Class A and Class B stock. The payment is scheduled for September 23, 2026.

Phibro Animal Health shares last closed at US$37.15, with a 1 month share price return of 11.7% but a 3 month share price return that declined 36.5%. Even so, the 1 year total shareholder return of 41.47% and 3 year total shareholder return of 160.59% indicate strong longer term momentum.

If this dividend update has you thinking about where else income or growth might come from, it could be worth scanning for established businesses with aligned leadership through the 19 top founder-led companies

Phibro Animal Health has surged over the past year yet pulled back sharply in recent months. Does that set up a fair entry today, or is it worth waiting to see if sentiment cools further before committing fresh capital?

Most Popular Narrative: 18.5% Undervalued

Analysts following Phibro Animal Health see a fair value of $45.60 per share, compared with the last close at $37.15. They anchor that gap to a long term earnings and margin story that stretches out to 2029.

Phibro's strategic Phibro Forward initiative, focused on operational efficiency, global procurement, innovation, and margin improvement, has already begun to positively impact profitability and is expected to continue driving growth in EBITDA and net margins through at least fiscal 2027. Robust performance across core business lines, including double digit growth in Vaccines and Nutritional Specialties, highlights Phibro's successful diversification beyond legacy antibiosis, positioning the company to benefit from industry trends moving toward antibiotic alternatives and higher margin health solutions, underpinning future revenue and margin expansion.

Curious what sits behind that margin story for Phibro Animal Health? The narrative leans on a specific revenue glide path, expanding profitability and a future earnings multiple that needs to hold up. The exact mix of growth, margins and discount rate doing that work may surprise you.

Result: Fair Value of $45.60 (UNDERVALUED)

However, there are still meaningful risks for Phibro Animal Health if regulatory pressure on antibiotics tightens further or if growth investments and acquisitions deliver weaker than expected returns.

Next Steps

Given the mix of enthusiasm and caution around Phibro Animal Health, it makes sense to move quickly and test the numbers yourself, then weigh the 3 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Phibro Animal Health?

If Phibro Animal Health has you thinking more seriously about your portfolio, do not stop here. The right mix of quality, income, and resilience often sits just outside your current watchlist.

• Target steadier portfolios by screening for companies that score well on resilience and financial risk using the 82 resilient stocks with low risk scores.
• Explore ways to support your income stream by checking out stocks that feature regular payouts through the 7 dividend fortresses.
• Identify potential standouts early by scanning the screener containing 18 high quality undiscovered gems before other investors start paying attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.